The regulation is compact and revolves around several discrete legal concepts that it either defines or operationalises. Each concept is anchored to specific provisions.

• Stock food. The regulation does not redefine stock food. It expressly adopts the meaning of "stock food" as given in the Biosecurity Act 2015 (reg 3). That means the regulated activities and obligations that refer to stock food must be read against the Biosecurity Act definition.

• Major food producing species. The regulation prescribes a specific list of types or species that constitute "major food producing species" for the Act, s 3(1), definition paragraph (b). The prescribed list is bees, ducks, farmed fish/farmed crustaceans/farmed molluscs, geese, goats and turkeys (reg 4). The regulation therefore sets the universe of animals to which any provisions of the Act that hinge on that definition will apply.

• Supplier disclosure for treated stock food. Reg 5 creates a supplier-side duty where a person supplies stock food knowing it has been treated with a stock medicine. The supplier must ensure the recipient is aware the food is treated, and must give "relevant details" the supplier obtained about when the stock food was obtained, or when the supplier obtained the stock medicine used to treat the food (reg 5(1)(a)-(b)(i)-(ii)). The regulation defines "relevant details" to mean written details about the use of the stock medicine, including the relevant withholding period for that stock medicine (reg 5(2)). Reg 5 also sets a maximum penalty for contraventions, quantified at 50 penalty units.

• Veterinary practitioner records. Reg 6 prescribes the exact contents of the records a veterinary practitioner must make for the purposes of the Act, s 39E. The list is comprehensive and enumerated: date of prescription/supply/use, identification particulars of the stock treated, owner or person in charge, particulars to identify the stock medicine, the name of the active constituent, the intended stock type, the withholding period (including recording that no withholding period was required, if applicable), dosage rate, frequency of treatment, length of treatment and manner of administration (reg 6(1)(a)-(k)). Reg 6(2) sets a minimum retention period of two years after the date of the prescription, supply or use.

• Advertising restrictions. Reg 7 targets stock medicines that contain substances listed in certain Poisons List schedules under the Poisons and Therapeutic Goods Act 1966 or, after the commencement of the 2022 Act, substances classified as Schedule 3, 4 or 8 under the Medicines, Poisons and Therapeutic Goods Act 2022 (reg 7(1)(a)-(b)). For those medicines the regulation prohibits advertising except in two narrow channels: journals with a circulation generally limited to veterinary practitioners, pharmacists or wholesalers of stock medicines, and documents or electronic communications intended for distribution exclusively to those professional groups (reg 7(2)(a)-(b)).

• Penalty notice framework. Reg 8 designates each offence listed in Schedule 1 as an offence for which a penalty notice may be issued under the Act, s 60A, and fixes the monetary amounts payable under those notices (reg 8(1)(a)-(b)). Reg 8(2) preserves a limiting principle: if the underlying statutory provision is qualified to a limited kind of offence or circumstances, a penalty notice can only be issued for that limited kind or those circumstances.

• Savings and continuity. Reg 9 protects existing legal effects created under the repealed 2019 regulation, stating that an act, matter or thing that had effect under the old regulation immediately before repeal continues to have effect under the new regulation (reg 9).

These concepts are expressed in operational terms, that is, the regulation provides specific procedural obligations and lists rather than general principles. The cross-references to other statutes embed the regulation within a wider legislative context, for example by relying on external definitions (stock food) and classification lists (Poisons List schedules) that affect the scope of advertising restrictions.

The regulation targets a narrow set of economic actors and professionals, and assigns differing obligations and potential enforcement exposure.

• Suppliers of stock food. Any person who supplies stock food to another person, and who knows that the stock food has been treated with a stock medicine, is subject to the disclosure obligations in reg 5(1). The supplier must ensure awareness and provide written "relevant details" as defined in reg 5(2). The supplier faces a maximum penalty of 50 penalty units for breach of reg 5(1).

• Veterinary practitioners. Reg 6 applies to veterinary practitioners for the purposes of the Act, s 39E. A veterinary practitioner must record specified data fields when prescribing, supplying or using a stock medicine and retain those records for at least two years (reg 6(1)-(2)). This places record-keeping duties and retention obligations on registered veterinary professionals.

• Advertisers, manufacturers, wholesalers and pharmacists. Reg 7 restricts advertising of stock medicines that contain specified poisonous substances or, after a statutory change, Schedule 3/4/8 substances under the Medicines, Poisons and Therapeutic Goods Act 2022. The prohibition applies to advertising outside professional channels. The permitted channels are journals with circulation generally limited to veterinary practitioners, pharmacists or wholesalers of stock medicines, and documents or electronic communications intended exclusively for those groups (reg 7(2)). Entities involved in marketing or distributing stock medicines, including manufacturers, wholesalers and pharmacists, must therefore confine promotional communications for such products to those professional channels.

• Owners and persons in charge of stock. While the regulation does not impose direct new duties on every owner, it affects owners indirectly. Suppliers and veterinary practitioners are required to provide or record details that identify the owner or person in charge of the stock (reg 6(1)(c); reg 5(1)). Owners will therefore be recipients of information and may be named in veterinary records.

• Corporations and individuals carrying out regulated activities. Schedule 1 attaches fixed penalty notice amounts separately for individuals and corporations for specific offences under the Act (Schedule 1 table). For example, offences under the Act s 39D(1) attract $1,100 for an individual and $2,200 for a corporation if enforced by penalty notice. The differential amounts signal that corporate actors face higher fixed penalties.

• Regulatory administrators and enforcement agencies. The regulation empowers issuance of penalty notices for the Schedule 1 offences via reg 8(1). Enforcement agencies charged with administering the Act will therefore have the option to use penalty notices as an enforcement tool for the listed offences, subject to reg 8(2) limiting issuance to the qualified kinds or circumstances where applicable.

The list of affected parties is concrete and limited. The regulation mainly reallocates record-keeping, disclosure and advertising responsibilities to suppliers, veterinary practitioners, manufacturers, wholesalers and pharmacists, as well as subjecting those actors to the penalty notice regime for certain contraventions.

The regulation establishes several affirmative duties and limited permissions tied to specified conduct. Below are the core duties and the operational rights or narrow permissions the regulation creates.

Duties

• Supplier disclosure when stock food is treated. A person who supplies stock food to another person, knowing the food has been treated with a stock medicine, must ensure the recipient is aware the stock food has been treated, and must give written "relevant details" which the supplier obtained about either when the supplier obtained the stock food, or when the supplier obtained the stock medicine used to treat it (reg 5(1)(a)-(b)(i)-(ii); reg 5(2)). The obligation is knowledge-based, so it hinges on the supplier's knowledge that the food was treated. The maximum penalty for breaching reg 5(1) is 50 penalty units, as specified in the same provision.

• Veterinary practitioner record-keeping and retention. Veterinary practitioners must record the enumerated items at the time of prescription, supply or use of a stock medicine: date; stock identification details; owner or person in charge; particulars to identify the medicine; name of the active constituent; intended type of stock; withholding period (including explicit recording that none was required where applicable); dosage rate; frequency; length of treatment; and manner of administration (reg 6(1)(a)-(k)). Those records must be retained for at least two years from the date of the relevant prescription, supply or use (reg 6(2)). The duty is specific and prescriptive about content and retention period.

• Advertising limitations. Persons must not advertise stock medicines that contain certain Schedule 3, 4 or 8 substances or those listed in Schedules Three, Four or Eight of the Poisons List, except in a journal whose circulation is generally limited to veterinary practitioners, pharmacists or wholesalers, or in a document or electronic communication intended exclusively for those groups (reg 7(1)-(2)). This is a restrictive duty, reducing permissible advertising outlets to professional channels only.

Permissions and boundaries

• Narrow permitted advertising channels. The regulation does not ban all advertising of stock medicines, it permits advertising but only in specified professional channels. That is an operational permission for manufacturers, wholesalers and pharmacists to communicate about such medicines, provided the medium meets the restricted circulation or exclusive-intent criteria in reg 7(2).

• Penalty notice option. The regulation allows enforcement to proceed via penalty notices for the offences listed in Schedule 1, with fixed amounts for individuals and corporations (reg 8(1); Schedule 1). This is an administrative enforcement pathway, giving regulators an alternative to court proceedings for the listed offences. Reg 8(2) limits penalty notices to the kinds or circumstances specified when the underlying provision is so qualified.

Contingent and interpretive points in the duties

• Knowledge threshold. The supplier duty in reg 5 is triggered by the supplier "knowing" that the food has been treated. The regulation does not further define "knowing". Whether constructive knowledge or reasonable enquiry obligations arise will depend on statutory interpretation under the Act and applicable common law, but the regulation itself sets the duty on actual knowledge.

• Content of "relevant details". The regulation defines relevant details as written details about the use of the stock medicine, including the withholding period (reg 5(2)). That imposes a written-information standard, and an express requirement to disclose withholding periods, including where none applies, as reflected in the veterinary practitioner's record duty (reg 6(1)(g)).

• Record retention period specified. The two-year minimum retention for veterinary records is absolute in the regulation (reg 6(2)). The regulation does not create variable retention periods or exceptions.

These duties and permissions are procedural and prescriptive. They allocate duties to identifiable actors, specify the form of disclosure or record-keeping (written, listed fields), and narrow permissible advertising outlets. The penalty notice schedule operationalises enforcement as fixed monetary amounts for particular statutory offences under the Act.

The regulation creates both criminal penalties by cross-reference to the Act and a structured penalty notice regime for certain offences. It therefore affects both substantive exposure and administrative enforcement choices.

Maximum penalties in the regulation

• Supplier contravention penalty. Reg 5(1) includes a maximum penalty for the supplier disclosure duty, set at 50 penalty units. The regulation does not convert that penalty into a dollar amount; the value of a penalty unit is determined under the general penalty unit provisions applicable to the jurisdiction. The regulation states the quantum as 50 penalty units explicitly.

Penalty notice scheme and fixed amounts

• Reg 8 implements the penalty notice mechanism for the offences listed in Schedule 1, specifying that each listed offence is one for which a penalty notice may be issued under the Act, s 60A (reg 8(1)(a)-(b)). The regulation fixes the amounts payable under such notices by reference to Schedule 1 (reg 8(1)(b)). The Schedule sets dollar amounts, distinguishing between individuals and corporations.

• Schedule 1 lists offences under the Act (not the regulation) and attaches explicit dollar figures. Examples include:

  • Offences under the Act, s 39C(1), s 39C(2), s 39C(3), s 39E and s 39F carry penalty notice amounts of $550 for an individual and $1,100 for a corporation.
  • Offences under the Act, s 39D(1), s 40(2), s 40A(1A), s 43(1) and s 46(6) carry amounts of $1,100 for an individual and $2,200 for a corporation. The Schedule is explicit in these figures; it does not provide any further gradation.

Limits on penalty notice issuance

• Reg 8(2) qualifies the penalty notice power: where the underlying statutory provision is itself limited by words that restrict operation to a limited kind or circumstances, a penalty notice may be issued only for that limited kind or those circumstances. This retains some connection between the scope of the original statutory offence and the administrative power to issue a penalty notice.

Enforcement pathways

• Administrative enforcement via penalty notices. The regulation provides for enforcement of certain offences through fixed-amount penalty notices, enabling an administratively efficient alternative to prosecution. The amounts are fixed in Schedule 1 and provide clarity about the immediate consequence of receiving a penalty notice for those specific offences.

• Criminal prosecution remains available. The regulation does not remove the prosecutorial pathway for offences under the Act. It simply designates particular offences as eligible for penalty notices and fixes the monetary amount payable under a notice.

Who pays and differentials

• Corporate premium. Schedule 1 distinguishes between individuals and corporations, with corporations facing double the individual amount in each listed offence entry. For example, an offence carrying $550 for an individual will attract $1,100 for a corporation, per the Schedule.

Practical enforcement implications

• Certainty of fixed amounts. The fixed amounts in Schedule 1 give regulated entities immediate information about the cost of non-compliance if enforcement is pursued by penalty notice rather than prosecution.

• Interaction with maximum penalties. For some contraventions the regulation also specifies maximum penalties (for example reg 5(1) is 50 penalty units). That maximum exposure via the court process may exceed the fixed penalty notice amount set in Schedule 1 for related offences under the Act. The regulator retains discretion whether to proceed by penalty notice (where available) or by prosecution.

• Administrative discretion subject to qualification. Reg 8(2) preserves certain statutory limitations on when a penalty notice may be issued, which affects the regulator's discretion in practice.

Overall, the regulation furnishes an administrative enforcement tool with fixed monetary values for a subset of Act offences while leaving prosecution available as an alternative. It also preserves higher statutory maxima in certain places, notably the supplier disclosure maximum of 50 penalty units.

The regulation is explicitly framed to operate in concert with several primary statutes and existing instruments. It functions as an implementation layer by referencing and relying upon external definitions, schedules and procedural provisions.

Primary interactions identified in the text

• Stock Medicines Act 1989. The regulation repeatedly operates "for the Act", supplying details that the Act calls for but does not itself specify. Examples include prescribing the species that count as "major food producing species" for the Act, s 3(1)(b) (reg 4), prescribing record-keeping requirements for veterinary practitioners for the Act, s 39E (reg 6), and designating penalty notice offences for the Act, s 60A (reg 8). In short, the regulation fleshes out the Act's operational requirements.

• Biosecurity Act 2015. Reg 3 adopts the Biosecurity Act 2015 definition of "stock food". That means the meaning of "stock food" for the purposes of obligations in this regulation derives from the Biosecurity Act. Any changes to that definition in the Biosecurity Act will therefore alter the scope of this regulation's obligations without amendment to the regulation itself.

• Poisons and Therapeutic Goods Act 1966. Reg 7(1)(a) refers to substances specified in Schedule Three, Four or Eight of the Poisons List as proclaimed under the Poisons and Therapeutic Goods Act 1966, s 8. The set of substances listed in those schedules therefore determines which stock medicines fall under the advertising restrictions in reg 7. Changes to the Poisons List schedules will influence the coverage of the advertising ban.

• Medicines, Poisons and Therapeutic Goods Act 2022. Reg 7(1)(b) anticipates and incorporates the classification schema under the 2022 Act by referring to Schedule 3, 4 or 8 substances within the meaning of that Act, "after the commencement" of its s 4(2). This forward-looking cross-reference means that, once the 2022 Act's particular provision is in force, the regulation's advertising restrictions will apply to substances as classified under that later Act.

• Subordinate Legislation Act 1989. The commencement note (reg 2) states that this regulation replaces the Stock Medicines Regulation 2019, which is repealed on commencement "by the Subordinate Legislation Act 1989, section 10(2)". That places the replacement in the procedural context of the subordinate legislation framework.

Interpretive and operational consequences

• Dynamic scope via external lists and definitions. Because the regulation relies on definitions and lists in other statutes, its substantive scope is partly determined by instruments outside its text. For advertising, the set of controlled substances depends on the Poisons List and on the later 2022 Act classifications. For "stock food", the Biosecurity Act supplies the base definition. That creates a regulatory coupling in which amendments to those other laws or proclaimed lists will change what this regulation covers.

• Coherent enforcement with the Act. The regulation's identification of penalty notice offences under the Act, s 60A, aligns the administrative enforcement mechanism with the Act’s enforcement architecture. The regulation does not create standalone criminal offences; rather, it specifies where penalty notices may be used as an enforcement option for Act offences.

• Potential for interpretive questions. Cross-referencing external statutes raises interpretive issues that will require alignment across instruments. For example, whether an animal falls within the "major food producing species" for particular Act provisions depends on reg 4's list, but the consequences of that classification derive from the Act’s treatment of "major food producing species". Where external statutes use overlapping terminology differently, resolving inconsistency will require statutory interpretation.

• Savings continuity. Reg 9 ensures continuity of legal effects that existed under the 2019 regulation, reducing the risk of regulatory gaps at the point of repeal and commencement.

In sum, the regulation operates as a detail-setting instrument that depends on, and interacts with, primary Acts and proclaimed lists. Its reach is partly dynamic because it incorporates definitions and schedules maintained elsewhere. Administrators, regulated parties and advisers need to track changes to the Biosecurity Act, the Poisons List and the Medicines, Poisons and Therapeutic Goods Act 2022 to understand evolving coverage.

The regulation in the text is a new instrument implemented on a specified commencement date and replaces the prior regulation. The text provides a concise amendment history confined to replacement and repeal events.

• Enactment and commencement. The regulation is identified as the Stock Medicines Regulation 2024 (reg 1). It commences on 1 September 2024 (reg 2). No other commencement phases or staggered commencement dates are provided.

• Replacement of previous regulation. The commencement provision explicitly states that this regulation replaces the Stock Medicines Regulation 2019, and that the 2019 regulation is repealed on 1 September 2024 by operation of the Subordinate Legislation Act 1989, s 10(2), referenced in the commencement note (reg 2). The text thereby records that the 2019 regulation is the immediately preceding subordinate instrument.

• No amending schedules or transitional provisions beyond savings. Apart from the savings provision in reg 9, which preserves the effect of acts, matters or things that had effect under the repealed 2019 regulation immediately before repeal, the regulation contains no other transitional, sunset or amendment clauses. Reg 9 is the sole transitional mechanism noted in the instrument.

• No internal amendment history recorded. The supplied text does not list any prior amendments to the 2024 regulation itself, and does not show any historic versions, amendment dates, or legislative history beyond the stated replacement of the 2019 regulation. The regulation therefore appears as a fresh, consolidated instrument effective from the stated commencement date.

• Cross-references to future statutory changes. Reg 7 anticipates the operation of the Medicines, Poisons and Therapeutic Goods Act 2022, specifying that after commencement of its s 4(2) the regulation will treat Schedule 3, 4 or 8 substances within the meaning of that Act as falling within the scope of its advertising restrictions (reg 7(1)(b)). This is not an amendment to the regulation, but it expressly links regulatory effect to future commencement of provisions in another Act.

Practical implications for amendment monitoring

• Track external instruments rather than frequent amendments to this regulation. Given the regulation’s reliance on definitions and lists in other statutes, substantive changes to coverage are more likely to come from amendments or proclamation changes in those external instruments (for example the Poisons List or the Biosecurity Act) than from frequent text changes to the regulation itself.

• Transitional certainty via savings. The single transitional device, reg 9, means that actions taken under the 2019 regulation immediately before repeal retain legal effect under the new regulation, reducing immediate transitional risk at the point of swap-over.

The text contains no further recorded amendments or historical variations. For a full legislative history beyond what is provided, users will need to consult the parliamentary and gazettal records corresponding to enactment, but the instrument itself records only the replacement of the 2019 regulation and the commencement date.

The regulation text contains no references to judicial decisions, precedent, or prior litigation. It does not name any cases or adjudicative outcomes. Given the absence of litigation references in the instrument, the text does not provide any litigation history for its provisions or for the 2019 regulation it replaces.

Nevertheless, the instrument creates several concrete points where future litigation or interpretive disputes could arise. These are areas the regulation itself leaves to be resolved either by administrative guidance or judicial interpretation:

• The knowledge threshold in supplier obligations. Reg 5(1) imposes duties on a supplier "knowing" the food has been treated with a stock medicine. The regulation does not define "knowing", so questions could arise about the standard of knowledge required, whether constructive knowledge or a duty to inquire is relevant, and what evidence demonstrates knowledge for enforcement purposes (reg 5(1)).

• The meaning and sufficiency of "relevant details" as written details. Reg 5(2) defines "relevant details" to mean written details about the use of the stock medicine, including the withholding period. Litigation could test what level of detail satisfies this written-information requirement, for example whether shorthand, electronic messages or labelling suffice, or whether additional information is required to be "about the use" (reg 5(2)).

• Compliance with the "ensure the other person is aware" obligation. Reg 5(1)(a) places an obligation on the supplier to ensure awareness. Practical questions could arise about reasonable steps required to create awareness, and whether the duty is satisfied by providing written details alone. That will affect enforcement outcomes.

• Advertising "intended for distribution exclusively" phrasing. Reg 7(2)(b) permits advertising in documents or electronic communications intended for exclusive distribution to specified professional groups. Disputes could occur about whether an electronic communication is sufficiently targeted or exclusive in distribution, or about whether a journal's stated circulation is "generally limited" to the listed professionals (reg 7(2)(a)-(b)).

• Interaction with external schedules. Reg 7(1)(a)-(b) links advertising coverage to external classification lists. Litigation could arise over whether a particular substance is properly classified under the Poisons List schedules or under the definition in the 2022 Act after its commencement, with implications for the advertising prohibition.

• Scope of offences for penalty notices. Reg 8(2) limits issuance of penalty notices where the underlying provision is qualified. Legal argument could occur over whether an alleged contravention falls within the "limited kind" or "limited circumstances" that permit a penalty notice, especially where facts are disputed.

The regulation itself does not supply litigated interpretive answers. Parties involved in enforcement or contesting penalty notices should expect potential arguments to focus on the statutory terms reproduced above. The text provides the legal framing for those disputes but no adjudicative history.

The regulation is compact but contains several practical pitfalls and compliance traps that regulated parties should note. These are drawn directly from the text and its operational mechanics.

• Knowledge trigger versus duty to investigate. Reg 5(1) makes the supplier obligation contingent on the supplier "knowing" the stock food has been treated. A gotcha is assuming mere suspicion or possibility triggers the duty. The regulation does not state that reasonable suspicion or constructive knowledge suffices. Conversely, a supplier who fails to make reasonable enquiries and is later found to have known could be exposed. Parties must treat the knowledge threshold as potentially decisive in enforcement (reg 5(1)).

• Written "relevant details" requirement is specific. Reg 5(2) requires written details about the use of the stock medicine including the withholding period. A common practical error would be relying solely on oral assurance to satisfy the duty. The regulation mandates written details as the defined "relevant details". Suppliers should therefore provide written material that explicitly sets out the withholding period or that records explicitly that there is no withholding period (reg 5(2); reg 6(1)(g)).

• Record fields are granular. Veterinary practitioners must capture a long list of discrete fields (reg 6(1)(a)-(k)). Omitting any one of these fields risks non-compliance. Notably the withholding period must be recorded, and the practitioner must note if there was no withholding period required. The retention period is a minimum of two years (reg 6(2)). A gotcha is failing to maintain records in a retrievable, durable format for the full two-year period.

• Advertising permitted only in narrow channels. Reg 7(2) carves out a narrow set of channels for advertising certain stock medicines. A practical trap is treating general professional websites, social media groups or widely circulated newsletters as permissible. The regulation limits permitted advertising to journals "with a circulation generally limited to veterinary practitioners, pharmacists or wholesalers of stock medicines" and documents/electronic communications "intended for distribution exclusively" to those three groups. Broadly accessible online advertisements, or emails that go beyond those exclusive audiences, are outside the exception and therefore unlawful for the medicines covered (reg 7(2)(a)-(b)).

• Dynamic scope via external lists. Because reg 7(1)(a)-(b) relies on the Poisons List and on definitions under the 2022 Act, the set of medicines captured by the advertising restriction can change without amendment to this regulation. A product currently permitted to be advertised to a wider audience might become restricted if later added to the relevant schedules. The practical gotcha is assuming coverage is static.

• Penalty notice amounts fixed and differential by corporate status. Schedule 1 sets fixed dollar amounts for penalty notices and doubles amounts for corporations relative to individuals. Entities that are incorporated should not assume the same penalty as an individual. Confusing penalty unit maxima with fixed Schedule 1 amounts is another common error; users must check both the maximum penalties under the Act/regulation and the Schedule 1 figures for available penalty-notice enforcement (reg 5; reg 8; Schedule 1).

• Confusing Act sections with regulation sections. Schedule 1 lists offences under the Act by reference to their Act section numbers (for example, s 39C, s 39E, s 43(1)). A compliance error would be to look for corresponding numbered sections inside the regulation. Advisers must map those Act section numbers to conduct obligations in the Act, not to provisions in the regulation.

• Retention formats and accessibility not specified. Reg 6(2) requires two-year retention by veterinary practitioners but does not specify acceptable formats or how records must be made available to regulators or owners. Failure to maintain records in a durable, readily accessible form could hinder demonstration of compliance in an enforcement context.

• Savings may mask past non-compliance. Reg 9 preserves legal effects from the repealed 2019 regulation. A practical issue is that conduct carried out under older processes might have continuing legal consequences under the new regulation; parties should review prior practices to ensure historical compliance aligns with the new prescriptive record and disclosure requirements (reg 9).

Recognising these gotchas will help regulated parties avoid routine non-compliance. The regulation's emphasis on written information, narrow advertising channels, and specified record fields means that form and audience control are material compliance parameters.

Compliance requires operationalising the specific duties in the regulation into business processes and record systems. Below are concrete, source-grounded steps that suppliers, veterinary practitioners, manufacturers, wholesalers and advertisers should implement to meet the regulation’s requirements.

For suppliers of stock food (reg 5)

• Establish a knowledge-control process. Because the obligation is triggered by the supplier knowing the food has been treated with a stock medicine, develop a chain-of-custody and notification procedure to capture when supplied stock food has been treated. Ensure staff understand that actual knowledge activates the requirement. If suppliers may obtain treated stock food incidentally, create intake checks to record the treatment status.

• Provide written "relevant details". Create a standard form or written statement that constitutes the "relevant details" as defined in reg 5(2). The form should include at minimum: the identifier of the stock food consignment, the date the supplier obtained the stock food and/or the date the supplier obtained the stock medicine used to treat it, the name of the stock medicine or its identifying particulars, and the withholding period for the stock medicine. Retain copies of every written disclosure given to recipients.

• Proof of delivery and awareness. Because the duty requires the supplier to ensure the other person is aware the food has been treated, maintain proof that the disclosure was delivered and that the recipient acknowledged receipt. A signed receipt, digital read-receipt, or other verifiable acknowledgement will assist in defending enforcement action.

For veterinary practitioners (reg 6)

• Record template and mandatory fields. Implement a record template capturing each of the elements in reg 6(1)(a)-(k): date, identifying details of stock, name of owner/person in charge, medicine particulars, active constituent, intended stock type, withholding period or explicit statement of none, dosage rate, frequency, length of treatment and manner of administration. Use electronic medical record systems with required fields to avoid omissions.

• Retention and backup. Ensure records are retained for at least two years after the date of prescription, supply or use (reg 6(2)). Build retention schedules into record management systems and ensure backups and access controls comply with privacy and professional standards.

• Proof of compliance for audits. Maintain an audit trail that links entries to the specific veterinary practitioner making the record. Time stamps and practitioner identification will be useful in any compliance review or enforcement action.

For advertisers, manufacturers and wholesalers (reg 7)

• Restrict marketing channels for specified medicines. Map your product list against the Poisons List schedules (Poisons and Therapeutic Goods Act 1966) and, after activation, the Schedule 3/4/8 classifications under the Medicines, Poisons and Therapeutic Goods Act 2022. For any medicine that falls within those schedules, confine promotional activity to:

  • journals whose circulation is generally limited to veterinary practitioners, pharmacists or wholesalers, and
  • documents or electronic communications intended exclusively for distribution to those professional groups (reg 7(1)-(2)). Maintain records that demonstrate the limited circulation or exclusive-intent distribution criteria were met for each advertisement.

• Targeted electronic communications. For electronic communications, use recipient lists and distribution controls that ensure exclusivity, for instance password-protected portals, member-only email lists restricted to registrants with professional credentials, or targeted mailings that require professional verification.

For corporate governance and compliance units

• Update policies and contracts. Revise supplier terms and conditions, sale agreements and distribution contracts to embed the disclosure requirements and to allocate responsibility for supplying the written "relevant details". Include warranties from suppliers regarding the accuracy of provided details.

• Training and standard operating procedures. Train staff in procurement, sales, veterinary practice, marketing and compliance on the new obligations. Provide checklists for intake of stock food, record-making by vets, and permissible advertising steps.

• Penalty notice exposure management. Familiarise the compliance team with Schedule 1 so they understand fixed penalty amounts and the differentiation between individuals and corporations. Consider internal escalation thresholds for potential breaches that might attract penalty notices and maintain adequate reserves or insurance where appropriate.

Monitoring and audit

• Regular compliance audits. Conduct periodic audits of veterinary records to ensure completeness of reg 6 fields and of supplier disclosures to ensure written "relevant details" are being provided and properly stored.

• Track external lists and definitions. Because the regulation relies on external definitions and Poisons List schedules, establish a monitoring arrangement to track changes in the Biosecurity Act definitions, the Poisons List and commencement of the 2022 Act provisions that affect classification. Changes there may expand or narrow obligations under reg 7 and reg 3.

Documentation and evidentiary practice

• Keep copies of all written disclosures and acknowledgements. Retain both the disclosed document given to the recipient and internal records showing the supplier’s basis for the disclosure (for example the date the supplier received the stock or the stock medicine), to demonstrate compliance if challenged under reg 5.

• Keep advertising evidence. For advertising permitted under reg 7, retain copies of the publication’s circulation statement, subscriber lists or distribution controls that evidence the "generally limited" or "exclusively intended" nature of the audience.

In short, compliance is best achieved by codifying the written disclosure and record-keeping requirements into forms and electronic systems, restricting marketing to clearly professional channels for specified medicines, and building monitoring mechanisms to track the external instruments on which the regulation relies.